Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.085 EUR
14.15 B EUR
40.68 B EUR
3.37 B
About Novo Nordisk A/S Class B
Sector
Industry
CEO
Maziar Mike Doustdar
Website
Headquarters
Bagsværd
Founded
1923
ISIN
US6701002056
FIGI
BBG000JPN1L2
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037Yield to maturity
3.51%
Maturity date
May 27, 2037
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034Yield to maturity
3.19%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033Yield to maturity
3.02%
Maturity date
May 27, 2033
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031Yield to maturity
2.79%
Maturity date
Jan 21, 2031
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030Yield to maturity
2.72%
Maturity date
Aug 27, 2030
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030Yield to maturity
2.63%
Maturity date
Mar 31, 2030
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028Yield to maturity
2.55%
Maturity date
May 27, 2028
N
XS282045460
Novo Nordisk Finance (Netherlands) BV 3.125% 21-JAN-2029Yield to maturity
2.50%
Maturity date
Jan 21, 2029
N
XS282044994
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2026Yield to maturity
2.43%
Maturity date
May 21, 2026
XS234803042
Novo Nordisk Finance (Netherlands) BV 0.125% 04-JUN-2028Yield to maturity
2.37%
Maturity date
Jun 4, 2028
XS244933017
Novo Nordisk Finance (Netherlands) BV 1.125% 30-SEP-2027Yield to maturity
2.26%
Maturity date
Sep 30, 2027
See all NOVA bonds
476070
SAMSUNG KODEX Global Obesity Treatment TOP2 Plus ETF UnitsWeight
23.87%
Market value
11.23 M
USD
476690
MIRAE ASSET TIGER GLOBAL OBESITY TREATMENT TOP 2 PLUS INDXX ETF UnitsWeight
23.44%
Market value
10.06 M
USD
LIFE.U
Evolve Global Healthcare Enhanced Yield Fund Trust Units USD UnhedgedWeight
4.74%
Market value
9.95 M
USD
Explore more ETFs
Curated watchlists where NOVA is featured.
